ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
The activity of niosomal serratiopeptidase enzyme in combination with palmitoleic acid in rats with insulin-resistant polycystic ovarian syndrome.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates the therapeutic potential of combining palmitoleic acid with niosomal serratiopeptidase in a rat model of insulin-resistant polycystic ovarian syndrome (PCOS). Niosomal serratiopeptidase was formulated by thin-film hydration and characterized for particle size, polydispersity index, zeta potential, and encapsulation efficiency. Thirty prepubertal female rats were divided into six groups (n = 5). A negative control (Group 1); PCOS rats (Group 2); PCOS rats treated with free niosomes (0.7 mg/kg, i.p.; Group 3); serratiopeptidase-loaded niosomes (1 mg/kg, i.p.; Group 4); palmitoleic acid (300 mg/kg, p.o.; Group 5); and a combination of serratiopeptidase-loaded niosomes plus palmitoleic acid (Group 6). PCOS was induced in groups 2-6 using letrozole plus a high-fat diet for 30 days, followed by 30 days of the respective treatments, after which body and ovarian weights, ovarian cysts, and histological and biochemical parameters were assessed. The niosomes prepared exhibited a size of 746.6 ± 54.1 nm and a PDI of 0.389 ± 0.03. Serratiopeptidase encapsulation efficiency was found to be around 74%. Compared with controls, the PCOS group exhibited estrous cycle irregularities and significant increases in ovarian volume (p < 0.01), ovarian index (ovarian weight/body weight × 100%; p < 0.01), cyst number (p < 0.01), fasting plasma glucose (p < 0.01-0.001), fasting insulin (p < 0.001), HOMA-IR (p < 0.001), luteinizing hormone (P < 0.001), and testosterone (p < 0.001), along with decreased follicle-stimulating hormone (p < 0.0001). While serratiopeptidase niosomes or palmitoleic acid alone partially improved PCOS parameters, including reductions in ovarian volume (p < 0.05) and metabolic and hormonal markers (p < 0.01-0.001), some effects did not reach statistical significance. In contrast, the combination of niosomal serratiopeptidase and palmitoleic acid produced the greatest effects, significantly improving metabolic, hormonal, and ovarian parameters toward near-normal levels (p < 0.05-0.0001). These preclinical findings suggest that niosomal serratiopeptidase combined with palmitoleic acid may represent a potential supportive therapeutic approach for PCOS; however, further clinical validation is warranted before any translational conclusions can be drawn.
Indexed as
Identifiers
42301352What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.